Mirvaso Gel (Brimonidine 0.33%)

Mirvaso is the new FDA approved treatment from Galderma that was previously known as Sansrosa, CD07805/47 and Col-118. Mirvaso is the only topical treatment officially approved for the relief of the red face of rosacea. Mirvaso is Brimonidine Topical Gel 0.33% and is available in 30g and 45g tubes, on prescription only. It is used once per day and can last as long as 12 hours.

See below for Mirvaso User Reviews, news and updates

Recent Rosacea Blog Posts

Actavis to trial Mirvaso competitor

An interesting development in rosacea clinical trials is the emergence of a new company called Actavis. Actavis have listed a large trial where they plan to test their Brimonidine Gel against Galderma’s recently FDA approved Brimonidine-based Mirvaso Gel. The large Phase 3 trial will compare the response after 7 days. Up to 462 patients in […]

Continue Reading

Galderma offers physicians advice for Mirvaso Rebound Redness

Galderma have added a page to the Mirvaso web site to guide doctors dealing with the potential for “rebound” by users of Mirvaso. This would seem to confirm that Galderma is aware that there are users of MIRVASO who are experiencing adverse events. The use of double quotes around “rebound” and “worsening” is interesting and […]

Continue Reading

New adverse allergic contact reaction to Mirvaso noted in JAAD

The latest edition of the Journal of American Academy of Dermatology lists an exchange by letter detailing a contact dermatitis allergic reaction to Mirvaso. The adverse reaction was found by the doctors to be caused by the main active ingredient in Mirvaso, Brimonidine. The writers of the letter to the JAAD caution other doctors that […]

Continue Reading

Mirvaso features in Sky TV’s My Naked Secret

Rosacea Forum user rosaceaclearwannabe has posted about a recent episode of My Naked Secret that features a participant who was treated with Mirvaso. The show follows Anna who suffers from the red face of rosacea. She is followed as she becomes one of the first people in Europe to try being treated with Mirvaso. The […]

Continue Reading

News today that the former owners of the patent covering the product Mirvaso have sued Galderma over a contract dispute. The 5 former owners of Sansrosa say that a contract error will cost them $20m. Sansrosa, who was then owned by Collagenex was sold to Galderma in 2008. Galderma asserts a group of patents protect […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.